Capricor Therapeutics, Inc.
CAPR
$6.97
$0.081.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -11.55% | 65.33% | 187.15% | 389.30% | 886.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -11.55% | 65.33% | 187.15% | 389.30% | 886.80% |
| Cost of Revenue | 37.10% | 38.53% | 54.44% | 63.72% | 67.06% |
| Gross Profit | -145.77% | -18.38% | 12.46% | 32.06% | 41.50% |
| SG&A Expenses | 16.08% | 15.19% | 15.91% | 19.10% | 22.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.63% | 32.20% | 43.13% | 49.65% | 52.74% |
| Operating Income | -76.78% | -17.13% | 1.55% | 12.95% | 18.92% |
| Income Before Tax | -81.57% | -16.64% | 4.38% | 16.07% | 23.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -81.57% | -16.64% | 4.38% | 16.07% | 23.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -81.57% | -16.64% | 4.38% | 16.07% | 23.20% |
| EBIT | -76.78% | -17.13% | 1.55% | 12.95% | 18.92% |
| EBITDA | -78.80% | -16.32% | 3.14% | 14.95% | 21.11% |
| EPS Basic | -37.47% | 7.86% | 20.23% | 25.01% | 26.31% |
| Normalized Basic EPS | -37.22% | 7.74% | 20.15% | 24.96% | 26.25% |
| EPS Diluted | -37.10% | 8.04% | 20.39% | 25.16% | 26.12% |
| Normalized Diluted EPS | -37.22% | 7.74% | 20.15% | 24.96% | 26.25% |
| Average Basic Shares Outstanding | 31.51% | 25.00% | 19.47% | 14.12% | 9.02% |
| Average Diluted Shares Outstanding | 31.51% | 25.00% | 19.47% | 14.12% | 9.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |